Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$825.42
+0.4%
$846.30
$711.40
$972.53
$782.64B0.343.31 million shs3.74 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$331.23
+1.0%
$333.68
$189.00
$377.46
$7.31B-0.41391,638 shs324,680 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$69.58
+0.4%
$82.15
$66.88
$148.15
$312.24B0.425.57 million shs6.82 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.62%-4.68%-10.32%+6.92%+6.10%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.02%-4.38%-2.94%+7.34%+24.04%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+0.32%-7.60%-23.26%-19.11%-45.81%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.7975 of 5 stars
2.45.03.34.03.42.51.9
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
3.4454 of 5 stars
2.40.00.04.62.34.20.6
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.811 of 5 stars
4.45.02.50.01.90.04.4
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7222.33% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.80
Moderate Buy$378.4414.25% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25108.75% Upside

Current Analyst Ratings Breakdown

Latest LLY, MDGL, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/27/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy$236.00 ➝ $422.00
2/27/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$378.00 ➝ $469.00
2/27/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$400.00 ➝ $405.00
2/12/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,000.00 ➝ $970.00
(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.38$13.46 per share61.34$15.05 per share54.85
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$180.13M40.60N/AN/A$20.53 per share16.13
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.08$3.23 per share21.57$4.64 per share15.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.4926.521.4023.51%85.24%16.19%5/1/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$373.63M-$22.11N/AN/AN/AN/A-71.78%-53.25%5/6/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2921.1514.930.9034.81%84.68%26.29%5/1/2025 (Estimated)

Latest LLY, MDGL, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/26/2025Q4 2024
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.26%+25.26%47.72%N/A

Latest LLY, MDGL, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.15
5.98
5.93
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
22.80%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.08 million16.84 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable

Recent News About These Companies

Novo Nordisk Stock (NVO) Drops Despite Positive GLP-1 Trial Data
Modern medical technology system and devices - stock image
Which Healthcare Stock Is the Best Buy Right Now? (NVO)
Novo Nordisk: Finally A Buying Opportunity
Investor Concerns Send Novo Nordisk Shares Tumbling

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$825.42 +2.91 (+0.35%)
Closing price 03/31/2025 03:59 PM Eastern
Extended Trading
$823.12 -2.30 (-0.28%)
As of 03/31/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$331.23 +3.36 (+1.02%)
Closing price 03/31/2025 04:00 PM Eastern
Extended Trading
$333.62 +2.39 (+0.72%)
As of 03/31/2025 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$69.58 +0.28 (+0.40%)
Closing price 03/31/2025 03:59 PM Eastern
Extended Trading
$69.48 -0.10 (-0.14%)
As of 03/31/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.